查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1654325

全球標靶蛋白質分解市場：市場規模、佔有率、趨勢分析（按類型、應用、最終用途和地區）、細分市場預測（2025-2030 年）

Targeted Protein Degradation Market Size, Share & Trends Analysis Report By Type (PROTAC, Molecular Glues), By Application (Drug Discovery, Therapy Development), By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

標靶蛋白質分解市場趨勢：

2024 年全球標靶蛋白質分解市場規模估計為 5.444 億美元，預計 2025 年至 2030 年的複合年成長率為 20.80%。

癌症和神經退化性疾病等慢性病的發生率不斷增加，以及生活方式的改變和醫療支出的增加，推動了市場的成長。這些疾病的高發性對新型治療方案產生了強烈需求，推動了市場成長。

例如，根據世界衛生組織（WHO）的資料，2022年將診斷出約2,000萬例新發癌症病例，並有970萬人死於癌症。此外，估計有 5,350 萬人在確診癌症後五年內仍會罹患癌症。

該領域研發活動的擴大將提供巨大的市場成長機會。例如，2023 年 12 月，奧地利科學基金 (FWF)核准了靶向蛋白質分解 (SFB) 特別研究計劃，第二個津貼期為四年。靶向蛋白質分解（SFB）特別研究計劃是一項研究舉措，重點是了解和開發針對特定蛋白質進行細胞分解的方法。該計畫旨在推動靶向蛋白質分解領域的發展，該領域近年來由於其在藥物發現和治療性介入的潛在應用而引起了廣泛關注。

支持性法規環境，尤其是 FDA 和 EMA 等機構簡化的核准流程，在加速採用基於 TPD 的治療方法方面發揮關鍵作用。平台技術的快速進步正在推動靶向蛋白質分解行業的發展。蛋白水解靶向嵌合體(PROTAC)、分子黏合劑和溶酶體靶向嵌合體(LYTAC) 等創新方法的開發擴展了 TPD 選擇性消除致病蛋白質的能力。這些技術突破為針對以前無法用藥的蛋白質開闢了新的途徑，推動了靶向蛋白質分解行業的成長。

人們越來越認知到標靶蛋白質分解對於解決以前無法治療的疾病的治療潛力，這是靶向蛋白質分解行業發展的主要驅動力。儘管傳統方法經常難以處理難以調控的蛋白質，但 PROTAC（蛋白質分解靶向嵌合體）等技術透過促進致病蛋白質的分解提供了有利的解決方案。這種方法在治療神經退化性疾病顯示出巨大的潛力，從而引發該領域的研究和投資激增。美國國立衛生研究院已將PROTAC列為現代藥物開發的旗艦技術。隨著臨床前和早期臨床試驗的成功率不斷提高，製藥和生物技術公司正在將標靶蛋白質分解整合到他們的產品線中，並認知到其改變治療策略的潛力。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

3. 標靶蛋白質分解市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 目標蛋白質分解市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL 分析
    • COVID-19影響分析

第 4 章 標靶蛋白質分解市場：按類型進行估計和趨勢分析

  • 細分儀表板
  • 標靶蛋白質分解市場：按類型進行差異分析
  • 標靶蛋白質分解市場：市場規模預測與趨勢分析（按類型）（2018-2030 年）
  • PROTAC
  • 分子黏合劑
  • LYTAC
  • 其他

第 5 章 標靶蛋白質分解市場：按應用的估計和趨勢分析

  • 細分儀表板
  • 標靶蛋白質分解市場：按應用進行的變化分析
  • 標靶蛋白質分解市場：按應用分類的市場規模預測和趨勢分析（2018-2030 年）
  • 藥物研發
  • 開發治療方法
    • 癌症
    • 神經病學
    • 感染疾病
    • 心血管疾病
    • 其他

第6章 標靶蛋白質分解市場：依最終用途的估計與趨勢分析

  • 細分儀表板
  • 靶向蛋白質分解市場：按最終用途進行的變化分析
  • 標靶蛋白質分解市場：按最終用途分類的市場規模預測和趨勢分析（2018-2030 年）
  • 製藥和生物技術公司
  • 學術研究所
  • 醫院和臨床實驗室

第7章靶向蛋白質分解市場：區域估計和趨勢分析

  • 各地區市場佔有率（2024 年及 2030 年）
  • 市場儀表板：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 公司/競爭對手分類
  • 戰略地圖
  • 企業市場分析（2024）
  • 公司簡介/上市公司
    • Bayer AG
    • Bio-Techne
    • BOC Sciences
    • BPS Bioscience, Inc.
    • BroadPharm
    • LifeSensors Inc.
    • MedChemExpress.
    • Merck KGaA
    • Promega Corporation
    • Thermo Fisher Scientific, Inc.
Product Code: GVR-4-68040-351-3

Targeted Protein Degradation Market Trends:

The global targeted protein degradation market size was estimated at USD 544.4 million in 2024 and is projected to grow at a CAGR of 20.80% from 2025 to 2030. The constantly growing frequency of chronic disease conditions such as cancer and neurodegenerative diseases, along with changing lifestyles and increasing healthcare spending, are accelerating the market growth. The high prevalence of these diseases creates a strong demand for novel treatment options, driving market growth.

For instance, data from the World Health Organization (WHO) indicates that in 2022, around 20 million individuals were newly diagnosed with cancer, and there were 9.7 million cancer-related deaths. It's estimated that 53.5 million people were living with cancer within five years after receiving their diagnosis.

The expanding number of research and development activities in this field provides significant market growth opportunities. For instance, in December 2023, the Austrian Science Fund (FWF) approved the Special Research Program (SFB) in Targeted Protein Degradation for a second funding period of another four years. The SFB in Targeted protein degradation is a research initiative focusing on understanding and developing methods to target specific proteins for cell degradation. This program aims to advance the field of targeted protein degradation, which has gained significant attention in recent years due to its potential applications in drug discovery and therapeutic interventions.

The supportive regulatory environment, particularly the streamlined approval processes by agencies such as the FDA and EMA, has played a crucial role in accelerating the adoption of TPD-based therapies. Rapid advancements in the underlying technologies drive the targeted protein degradation industry. The development of innovative approaches, such as proteolysis-targeting chimeras (PROTACs), molecular glues, and lysosome-targeting chimeras (LYTACs), has expanded TPD's capabilities to eliminate disease-causing proteins selectively. These technological breakthroughs have opened up new avenues for targeting previously undruggable proteins, driving the growth of the targeted protein degradation industry.

The increasing recognition of the therapeutic potential of targeted protein degradation in addressing previously undruggable targets is a key driver for the targeted protein degradation industry. Traditional approaches often struggle with proteins that are difficult to modulate, but technologies such as PROTACs (proteolysis-targeting chimeras) provide a favorable solution by promoting the degradation of disease-causing proteins. This method has shown considerable promise in treating conditions such as cancer and neurodegenerative disorders, sparking a surge in research and investment in this area. The National Institute of Health highlights PROTACs as a leading drug development technology in recent years. The increasing success in preclinical and early-phase clinical trials drives pharmaceutical and biotech companies to integrate targeted protein degradation into their pipelines, recognizing its potential to transform therapeutic strategies.

Global Targeted Protein Degradation Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global targeted protein degradation market report based on type, application, end-use, and region.

  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • PROTAC
  • Molecular Glues
  • LYTACs
  • Others
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Drug Discovery
  • Therapy Development
    • Cancer
    • Neurology
    • Infectious Diseases
    • Cardiovascular Diseases
    • Others
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Hospitals & Clinical Laboratories
  • Others
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Type Segment
    • 1.2.2. Application Segment
    • 1.2.3. End Use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Targeted Protein Degradation Market Variables & Trends

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Growing frequency of chronic diseases
      • 3.2.1.2. Research and development activities
      • 3.2.1.3. Increasing recognition of the therapeutic potential of targeted protein degradation
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost
      • 3.2.2.2. Stringent regulations associated with approvals for novel TPD based therapies
  • 3.3. Targeted Protein Degradation Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Targeted Protein Degradation Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Targeted Protein Degradation Market Type Movement Analysis
  • 4.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. PROTAC
    • 4.4.1. PROTAC market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Molecular Glues
    • 4.5.1. Molecular Glues market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. LYTACs
    • 4.6.1. LYTACs market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Targeted Protein Degradation Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Targeted Protein Degradation Market Application Movement Analysis
  • 5.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Drug Discovery
    • 5.4.1. Drug Discovery market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Therapy Development
    • 5.5.1. Therapy Development market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Cancer
      • 5.5.2.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.3. Neurology
      • 5.5.3.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.4. Infectious Diseases
      • 5.5.4.1. Infectious Diseases market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.5. Cardiovascular Diseases
      • 5.5.5.1. Cardiovascular Diseases market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.6. Others
      • 5.5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Targeted Protein Degradation Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Targeted Protein Degradation Market End Use Movement Analysis
  • 6.3. Global Targeted Protein Degradation Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical & Biotechnology Companies
    • 6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Academic & Research Institutes
    • 6.5.1. Academic & Research Institutes market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Hospitals & Clinical Laboratories
    • 6.6.1. Hospitals & Clinical Laboratories market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Targeted Protein Degradation Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. Target disease prevalence
      • 7.4.2.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Target disease prevalence
      • 7.4.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. Target disease prevalence
      • 7.4.4.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Target disease prevalence
      • 7.5.2.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Target disease prevalence
      • 7.5.3.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. Target disease prevalence
      • 7.5.4.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Target disease prevalence
      • 7.5.5.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Target disease prevalence
      • 7.5.6.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Target disease prevalence
      • 7.5.7.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Competitive scenario
      • 7.5.8.3. Regulatory framework
      • 7.5.8.4. Target disease prevalence
      • 7.5.8.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.9. Denmark
      • 7.5.9.1. Key country dynamics
      • 7.5.9.2. Competitive scenario
      • 7.5.9.3. Regulatory framework
      • 7.5.9.4. Target disease prevalence
      • 7.5.9.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Target disease prevalence
      • 7.6.2.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Target disease prevalence
      • 7.6.3.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Target disease prevalence
      • 7.6.4.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Target disease prevalence
      • 7.6.5.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Target disease prevalence
      • 7.6.6.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Competitive scenario
      • 7.6.7.3. Target disease prevalence
      • 7.6.7.4. Regulatory framework
      • 7.6.7.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Target disease prevalence
      • 7.7.2.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Target disease prevalence
      • 7.7.3.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Target disease prevalence
      • 7.8.2.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Competitive scenario
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. Target disease prevalence
      • 7.8.3.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Competitive scenario
      • 7.8.4.3. Regulatory framework
      • 7.8.4.4. Target disease prevalence
      • 7.8.4.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key country dynamics
      • 7.8.5.2. Competitive scenario
      • 7.8.5.3. Regulatory framework
      • 7.8.5.4. Target disease prevalence
      • 7.8.5.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024
  • 8.4. Company Profiles/Listing
    • 8.4.1. Bayer AG
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Type benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Bio-Techne
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Type benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. BOC Sciences
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Type benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. BPS Bioscience, Inc.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Type benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. BroadPharm
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Type benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. LifeSensors Inc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Type benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. MedChemExpress.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Type benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Merck KGaA
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Type benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Promega Corporation
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Type benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Thermo Fisher Scientific, Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Type benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Global Targeted protein degradation market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 4 Global Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 5 Global Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 6 North America Targeted protein degradation market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 8 North America Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 9 North America Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 10 U.S. Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 12 U.S. Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Canada Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 14 Canada Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 15 Canada Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 16 Mexico Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 17 Mexico Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 18 Mexico Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 19 Europe Targeted protein degradation market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 21 Europe Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 23 Germany Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 24 Germany Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 25 Germany Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 UK Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 27 UK Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 28 UK Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 29 France Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 30 France Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 31 France Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 32 Italy Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 33 Italy Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 34 Italy Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Spain Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 36 Spain Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 37 Spain Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 38 Denmark Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 39 Denmark Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 40 Denmark Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 Sweden Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 42 Sweden Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 43 Sweden Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 44 Norway Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 45 Norway Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 46 Norway Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Targeted protein degradation market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 51 China Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 52 China Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 53 China Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Japan Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 55 Japan Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 56 Japan Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 57 India Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 58 India Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 59 India Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 60 South Korea Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 61 South Korea Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 62 South Korea Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 Australia Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 64 Australia Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 65 Australia Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 66 Thailand Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 67 Thailand Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 68 Thailand Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 69 Latin America Targeted protein degradation market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 71 Latin America Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 72 Latin America Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 73 Brazil Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 74 Brazil Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 75 Brazil Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 76 Argentina Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 78 Argentina Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 79 MEA Targeted protein degradation market, by country, 2018 - 2030 (USD Million)
  • Table 80 MEA Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 81 MEA Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 82 MEA Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 83 South Africa Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Africa Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 89 UAE Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 90 UAE Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 91 UAE Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Targeted protein degradation market, by type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Targeted protein degradation market, by application, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Targeted protein degradation market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 Targeted Protein Degradation market: Market outlook
  • Fig. 5 Targeted Protein Degradation market: Segment outlook
  • Fig. 6 Targeted Protein Degradation market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 Targeted Protein Degradation market driver impact
  • Fig. 9 Targeted Protein Degradation market restraint impact
  • Fig. 10 Targeted Protein Degradation market: Type outlook and key takeaways
  • Fig. 11 Targeted Protein Degradation market: Type movement analysis
  • Fig. 12 PROTAC market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Molecular Glues market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 LYTACs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Targeted Protein Degradation market: Application outlook and key takeaways
  • Fig. 17 Targeted Protein Degradation market: Application movement analysis
  • Fig. 18 Drug Discovery market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Therapy Development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Infectious Diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Cardiovascular Diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Targeted Protein Degradation market: End Use outlook and key takeaways
  • Fig. 26 Targeted Protein Degradation market: End Use movement analysis
  • Fig. 27 Pharmaceutical & biotechnology companies market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 28 Academic & Research Institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Hospitals & Clinical Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Global Targeted Protein Degradation market: Regional outlook and key takeaways
  • Fig. 32 Global Targeted Protein Degradation market: Regional movement analysis
  • Fig. 33 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Key country dynamics
  • Fig. 35 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Target Disease Prevalence
  • Fig. 37 Key country dynamics
  • Fig. 38 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Target Disease Prevalence
  • Fig. 40 Key country dynamics
  • Fig. 41 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Target Disease Prevalence
  • Fig. 43 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Target Disease Prevalence
  • Fig. 47 Key country dynamics
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Target Disease Prevalence
  • Fig. 50 Key country dynamics
  • Fig. 51 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Target Disease Prevalence
  • Fig. 53 Key country dynamics
  • Fig. 54 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Target Disease Prevalence
  • Fig. 56 Key country dynamics
  • Fig. 57 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Target Disease Prevalence
  • Fig. 59 Key country dynamics
  • Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Target Disease Prevalence
  • Fig. 62 Key country dynamics
  • Fig. 63 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Target Disease Prevalence
  • Fig. 65 Key country dynamics
  • Fig. 66 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Target Disease Prevalence
  • Fig. 68 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Target Disease Prevalence
  • Fig. 72 Key country dynamics
  • Fig. 73 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Target Disease Prevalence
  • Fig. 75 Key country dynamics
  • Fig. 76 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Target Disease Prevalence
  • Fig. 78 Key country dynamics
  • Fig. 79 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Target Disease Prevalence
  • Fig. 81 Key country dynamics
  • Fig. 82 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Target Disease Prevalence
  • Fig. 84 Key country dynamics
  • Fig. 85 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Target Disease Prevalence
  • Fig. 87 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Target Disease Prevalence
  • Fig. 91 Key country dynamics
  • Fig. 92 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Target Disease Prevalence
  • Fig. 94 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Target Disease Prevalence
  • Fig. 98 Key country dynamics
  • Fig. 99 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Target Disease Prevalence
  • Fig. 101 Key country dynamics
  • Fig. 102 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Target Disease Prevalence
  • Fig. 104 Key country dynamics
  • Fig. 105 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Target Disease Prevalence